Monday, 23 May 2005: 1:10 PM-5:30 PM | |||
Room 118 (Science & Engineering Resource Center) | |||
Medicinal Chemistry (MEDI) | |||
Pharmaceutical Profiling II | |||
| Drug discovery research balances innovation of both potency and pharmaceutical properties. This symposium discusses state-of-the-art physicochemical, metabolic and toxicological property topics. While structure based design for potency optimization has been intensively studied, property based design concepts for absorption, pharmacokinetics and safety optimization are still emerging. Symposium topics explore the fundamentals and predictive approaches for transporters, CYP mechanisms, hERG, pharmacokinetics and toxicity. Concepts for increasing the impact of this information on drug discovery resarch projects through interfacing to teams, multivariate statistics, and applications in compound design will be discussed. Open discussion among speakers and with the audience will be facilitated as an important element of learning and advancement | |||
| Organizer: | Edward H. Kerns | ||
| Presider: | Edward H. Kerns | ||
| 1:10 PM | 229 | Preclinical Assessment of QT Liability and Proarrhythmic Risk Paul Levesque | |
| 1:50 PM | 230 | Pharmaceutical Profiling: The Interface between Drug-like Property Prediction and Application for Project Impact Li Di, Edward H. Kerns, Susan L. Petusky, Susan Q. Li, Hong Chen | |
| 2:30 PM | 231 | The Application of Pharmaceutical Profiling Data to Lead Identification and Optimization John Ellingboe | |
| 3:10 PM | Break | ||
| 3:25 PM | 232 | The use of in vitro profiling in the optimization of IMPDH inhibitors Murali Dhar | |
| 4:05 PM | 233 | Strategies and techniques for providing in vivo PK and tissue penetration data for drug discovery Timothy Olah | |
| 4:45 PM | Panel Discussion | ||
Back to The 37th Middle Atlantic Regional Meeting (May 22-25, 2005)